- Home
- ARMP vs NCSM Comparison
ARMP vs NCSM Comparison
Compare ARMP & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- NCSM
- Stock Information
- Founded
- ARMP N/A
- NCSM 2006
- Country
- ARMP United States
- NCSM United States
- Employees
- ARMP N/A
- NCSM N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- NCSM Oilfield Services/Equipment
- Sector
- ARMP Health Care
- NCSM Energy
- Exchange
- ARMP Nasdaq
- NCSM Nasdaq
- Market Cap
- ARMP 92.4M
- NCSM 76.3M
- IPO Year
- ARMP N/A
- NCSM 2017
- Fundamental
- Price
- ARMP $2.86
- NCSM $47.16
- Analyst Decision
- ARMP Strong Buy
- NCSM
- Analyst Count
- ARMP 1
- NCSM 0
- Target Price
- ARMP $9.00
- NCSM N/A
- AVG Volume (30 Days)
- ARMP 12.1K
- NCSM 19.6K
- Earning Date
- ARMP 11-12-2025
- NCSM 10-29-2025
- Dividend Yield
- ARMP N/A
- NCSM N/A
- EPS Growth
- ARMP N/A
- NCSM N/A
- EPS
- ARMP N/A
- NCSM 4.71
- Revenue
- ARMP $6,868,000.00
- NCSM $175,468,000.00
- Revenue This Year
- ARMP $8.43
- NCSM $9.11
- Revenue Next Year
- ARMP N/A
- NCSM $7.13
- P/E Ratio
- ARMP N/A
- NCSM $9.71
- Revenue Growth
- ARMP 84.67
- NCSM 19.31
- 52 Week Low
- ARMP $0.90
- NCSM $16.81
- 52 Week High
- ARMP $3.14
- NCSM $51.49
- Technical
- Relative Strength Index (RSI)
- ARMP 57.54
- NCSM 65.62
- Support Level
- ARMP $2.79
- NCSM $40.99
- Resistance Level
- ARMP $3.03
- NCSM $51.49
- Average True Range (ATR)
- ARMP 0.16
- NCSM 3.22
- MACD
- ARMP 0.01
- NCSM 0.55
- Stochastic Oscillator
- ARMP 62.16
- NCSM 69.97
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.